VALIANTLABValiant Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VALIANTLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 146.2% YoY
- • Profit growth: 826.2% YoY
- • Debt/Equity: 0.15
- • MACD: bullish
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 146.2% YoY
- • Profit growth: 826.2% YoY
- • Debt/Equity: 0.15
- • MACD: bullish
Bear case
- • ROE: -1.1%
- • ROCE: 0.1%
- • Volume: 0.9x 20-day average
- • Volatility: 51% annualized
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: -1.1%
- • ROCE: 0.1%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹5.94). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.